Dalgleish AG - Search Results

1

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG. Dredge K, et al. Among authors: dalgleish ag. Br J Cancer. 2002 Nov 4;87(10):1166-72. doi: 10.1038/sj.bjc.6600607. Br J Cancer. 2002. PMID: 12402158 Free PMC article.

2

A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.

Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling DI, Dalgleish AG. Marriott JB, et al. Among authors: dalgleish ag. Cancer Res. 2003 Feb 1;63(3):593-9. Cancer Res. 2003. PMID: 12566301

3

Thalidomide analogs as emerging anti-cancer drugs.

Dredge K, Dalgleish AG, Marriott JB. Dredge K, et al. Among authors: dalgleish ag. Anticancer Drugs. 2003 Jun;14(5):331-5. doi: 10.1097/00001813-200306000-00001. Anticancer Drugs. 2003. PMID: 12782937 Review.

4

Immunological effects of thalidomide and its chemical and functional analogs.

Dredge K, Marriott JB, Dalgleish AG. Dredge K, et al. Among authors: dalgleish ag. Crit Rev Immunol. 2002;22(5-6):425-37. Crit Rev Immunol. 2002. PMID: 12803319 Review.

5

Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.

Marriott JB, Dredge K, Dalgleish AG. Marriott JB, et al. Among authors: dalgleish ag. Curr Drug Targets Immune Endocr Metabol Disord. 2003 Sep;3(3):181-6. doi: 10.2174/1568008033340207. Curr Drug Targets Immune Endocr Metabol Disord. 2003. PMID: 12871024 Review.

6

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB. Dredge K, et al. Among authors: dalgleish ag. Microvasc Res. 2005 Jan;69(1-2):56-63. doi: 10.1016/j.mvr.2005.01.002. Microvasc Res. 2005. PMID: 15797261

7

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG. Galustian C, et al. Among authors: dalgleish ag. Cancer Immunol Immunother. 2009 Jul;58(7):1033-45. doi: 10.1007/s00262-008-0620-4. Epub 2008 Nov 14. Cancer Immunol Immunother. 2009. PMID: 19009291 Free PMC article.

8

CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.

Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, Muller G, Shire MG, Stirling D, Dalgleish AG. Marriott JB, et al. Among authors: dalgleish ag. J Immunol. 1998 Oct 15;161(8):4236-43. J Immunol. 1998. PMID: 9780198

9

Thalidomide as an emerging immunotherapeutic agent.

Marriott JB, Muller G, Dalgleish AG. Marriott JB, et al. Among authors: dalgleish ag. Immunol Today. 1999 Dec;20(12):538-40. doi: 10.1016/s0167-5699(99)01531-5. Immunol Today. 1999. PMID: 10562702 Review. No abstract available.

10

Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection.

Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Heriot AG, et al. Among authors: dalgleish ag. Br J Cancer. 2000 Mar;82(5):1009-12. doi: 10.1054/bjoc.1999.1034. Br J Cancer. 2000. PMID: 10737381 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

381 results

Search Page

Filters